患有GCK-MODY的妇女的怀孕和新生儿结局:基于标准化胰岛素方式的观察性研究
Cécile Ciangura1,2, Aurélien Seco3, Cécile Saint-Martin4,5
1Department of Diabetology, Pitié-Salpêtrière Hospital, Sorbonne University, AP-HP, Paris, France. cecile.ciangura@aphp.fr.
Diabetologia
|February 19, 2025
概括
在怀孕期间管理GCK-MODY是具有挑战性的. 使用超声监测和延迟胰岛素启动的策略,基于胎儿GCK基因型,改善胎儿预后和减少母亲低血糖症.
科学领域:
- 内分泌学 在内分泌学.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 遗传学 是一个遗传学.
背景情况:
- 葡萄糖酶 (GCK) 基因突变导致年轻人成熟期糖尿病 (MODY).
- 在怀孕期间管理GCK-MODY带来了独特的挑战.
- 需要标准化的胰岛素管理策略来优化孕产妇和新生儿的结果.
研究的目的:
- 评估两种标准化胰岛素策略,用于怀孕期间的GCK-MODY管理.
- 评估这些策略对怀孕和新生儿结果的影响.
- 确定胎儿GCK基因型对结果的影响.
主要方法:
- 一项前性观察性研究,比较了两种胰岛素启动策略.
- 孕产妇葡萄糖 (MG) 组:根据妊娠糖尿病值开始使用胰岛素.
- 胎儿生长 (FG) 组:基于胎儿腹周,以安全葡萄糖水平启动胰岛素.
主要成果:
- MG组比FG组更频繁,更早地开始胰岛素,降低葡萄糖,但患上更高的低血糖.
- 两组之间总体怀孕或新生儿结局没有显著差异.
- 对于妊娠年龄大 (LGA) 新生儿发生在0%的胎儿GCK变异与36%没有 (p=0.005).
结论:
- 胎儿GCK基因型,而不是治疗策略,主要决定了LGA率.
- 超声指导的胎儿生长监测与延迟的胰岛素启动提供了良好的胎儿预后.
- 这一策略将在GCK-MODY怀孕中最大限度地降低母亲低血糖的风险.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Pathophysiology of Diabetes
845
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
845
Insulin: Dosing Regimen and Adverse Effects
139
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
139
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131


